Benzyl (3R,4S)-3-(2-Bromoacetyl)-4-Ethylpyrrolidine-1-Carboxylate

Manufacture of the enantiomerically pure (3R,4S)-pyrrolidine scaffold proceeds through a chiral pool approach or asymmetric hydrogenation of a suitable pyrroline precursor. The benzyl carbamate protecting group is retained throughout the bromoacetylation step, which employs bromoacetyl bromide in anhydrous dichloromethane at −5 °C to 0 °C with triethylamine as acid scavenger. Post-reaction, the organic phase is washed with ice-cold 1 M hydrochloric acid to remove excess amine base, dried over magnesium sulfate, and concentrated under reduced pressure at a bath temperature not exceeding 35 °C to prevent thermal degradation of the β-bromo ketone moiety. Purity exceeding 98.5% by HPLC (UV detection at 210 nm, C18 column, acetonitrile/water gradient) is routinely achieved after silica gel flash chromatography with ethyl acetate/hexane as eluent. Residual palladium from any upstream hydrogenation step must be controlled below 10 ppm to avoid catalyst poisoning in subsequent transition metal-mediated couplings where the α-bromoketone serves as an electrophilic partner. Process-scale batches require rigorous exclusion of moisture; Karl Fischer titration of the final product typically returns water content below 0.05%. Storage under argon at −20 °C in amber glass containers is mandatory; exposure to ambient humidity for periods exceeding four hours results in detectable hydrolysis of the bromoacetyl group, as evidenced by the appearance of the corresponding hydroxymethyl derivative at m/z +18 in LC-MS analysis.

For GMP production of advanced intermediates, the compound is typically dissolved in anhydrous tetrahydrofuran and held at −78 °C under nitrogen for immediate use in subsequent displacement reactions. Primary occupational exposure control relies on closed-system transfer; the compound is a potent alkylating agent in vitro, and Ames testing conducted under OECD Guideline 471 recommends handling as a potential mutagen. Waste streams containing unreacted starting material are quenched with aqueous sodium thiosulfate solution before disposal, converting the electrophilic carbon-bromine bond to a non-reactive thiosulfonate adduct.

Dopamine D3 Receptor Ligand Intermediates with Imposed trans-Substitution Geometry

The 3,4-trans-substitution pattern enforced by the (3R,4S) configuration locks the ethyl and bromoacetyl vectors into a defined dihedral angle, a feature exploited in the construction of conformationally constrained dopamine D3 receptor modulators. In a representative synthesis sequence, the bromoacetyl moiety undergoes nucleophilic displacement with 4-(4-fluorophenyl)-1,2,3,6-tetrahydropyridine under basic conditions—anhydrous potassium carbonate, 1.5 equivalents, in acetonitrile at reflux for 6 to 8 hours—to form the amino ketone bridge. The reaction is monitored by TLC (silica gel, ethyl acetate/methanol 9:1 v/v); disappearance of the R_f 0.65 spot corresponding to the starting bromoketone indicates completion. Following aqueous workup and extraction into ethyl acetate, the crude amino ketone is reduced with sodium triacetoxyborohydride (2.0 equivalents) in 1,2-dichloroethane at room temperature, affording the secondary amine diastereomerically enriched at the newly created stereocenter.

Deprotection of the benzyl carbamate via catalytic hydrogenation—10% palladium on carbon, 5 bar hydrogen pressure, methanol, 25 °C, 3 hours—releases the free pyrrolidine, which is subsequently functionalized at the ring nitrogen with a substituted benzamide or aryl sulfonamide to complete the pharmacophore. The trans relationship between the ethyl substituent and the elaborated 2-aminoethyl side chain positions the aryl ring into the orthosteric binding pocket with a topology predicted by docking studies to achieve a selectivity ratio exceeding 100-fold over D2 receptor subtypes in radioligand displacement assays (agonist mode, [³H]7-OH-DPAT, human recombinant receptors expressed in CHO-K1 cells, assay performed per standard filtration protocol with non-specific binding defined by 10 μM (+)-butaclamol). Published structure-activity relationship data for this series indicate that inversion of the C-3/C-4 relative stereochemistry reduces binding affinity by approximately 1.8 log units, confirming the criticality of the fixed geometry imparted by the starting bromoketone chirality. Kilo-lab campaigns producing this intermediate class have been scaled to 15 kg input batches using jacketed 100 L glass-lined reactors, with the displacement step requiring controlled addition of the bromoacetyl pyrrolidine solution over 45 minutes to manage the exotherm, which can raise internal temperature by 12 °C if not paced.

Large-scale manufacture of pyridazinone-based antibacterial candidates uses the present bromoacetyl pyrrolidine as a key C-4 functionalized building block. The synthetic sequence that merges the pyrrolidine core with the heterocyclic pharmacophore begins with hydrazine hydrate condensation onto the bromoacetyl carbonyl under thermodynamic control. The bromoketone (1.0 equivalent) is added portionwise to a stirred solution of hydrazine monohydrate (3.0 equivalents) in ethanol at 0 °C; the mixture is then heated to 60 °C for 2 hours, during which time the intermediate hydrazone cyclizes to the 1,4,5,6-tetrahydropyridazine. The reaction course is distinctive by the color change from pale yellow to deep amber, and GC headspace analysis confirms evolution of one equivalent of HBr, trapped as ammonium bromide upon scrubbing through dilute ammonia solution.

The tetrahydropyridazine intermediate is oxidized to the fully aromatic pyridazinone using manganese dioxide (10 equivalents by weight) in toluene at 80 °C, a heterogeneous process requiring vigorous mechanical agitation to maintain the oxidant in suspension. Filtration through a Celite pad and concentration gives the pyridazinone, which is then elaborated at the lactam nitrogen with a benzyl or phenethyl group under Mitsunobu conditions—diisopropyl azodicarboxylate (1.3 equivalents), triphenylphosphine (1.3 equivalents), THF, 0 °C to room temperature over 18 hours. Final deprotection of the Cbz group followed by acylation with a substituted benzoic acid delivers the target antibacterial agent. Susceptibility testing against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300 using the broth microdilution method (CLSI M07-A9) for compounds derived from this scaffold has yielded minimum inhibitory concentration values in the range of 0.5 to 2 μg/mL, with the 3-ethyl substituent contributing to metabolic stability by blocking benzylic oxidation in human liver microsome incubation studies (pooled mixed-gender donors, 1 μM test compound, NADPH regeneration system, 37 °C, sample quenching at 0, 5, 15, 30, 60 minutes).

What Magnitude of Diastereoselectivity Is Achievable in C-C Bond Formation via the α-Bromoketone Enolate Trap?

The bromoacetyl group functions as more than an electrophile. Under strictly anhydrous conditions, the α-methylene protons situated between the carbonyl and the bromine atom possess a pKa amenable to deprotonation by lithium diisopropylamide (LDA, 1.05 equivalents, freshly prepared from diisopropylamine and n-butyllithium at −78 °C). The resulting lithium enolate can be trapped with reactive electrophiles—benzaldehyde, trimethylsilyl chloride, or allyl bromide—to yield α-functionalized-α-bromo ketones, which retain the bromine for a subsequent displacement cascade. The stereochemical outcome of electrophilic addition to the enolate is governed by the fixed chirality of the C-3 and C-4 stereocenters on the pyrrolidine ring, which project a steric blocking group that directs approach of the electrophile to the less hindered si-face of the enolate. Diastereomeric ratios measured by analytical HPLC (Chiralpak IA column, 250 × 4.6 mm, hexane/isopropanol 95:5, 1.0 mL/min) for benzaldehyde addition routinely exceed 9:1 when the reaction is conducted at −95 °C in a THF/diethyl ether (1:1 v/v) mixed solvent system, conditions that favor an aggregated enolate structure with enhanced facial bias.

The α-benzylated bromoketone that results is then treated with a primary amine—typically 4-methoxybenzylamine (2.0 equivalents)—in acetonitrile with triethylamine (2.5 equivalents) at 50 °C to promote displacement of bromide and subsequent cyclization to an α-amino ketone intermediate. Reduction with sodium borohydride in methanol at 0 °C for 30 minutes affords a substituted ethanolamine derivative with three contiguous stereocenters. The Cbz group is ultimately hydrogenolyzed, and the free pyrrolidine nitrogen is coupled to an aryl carboxylic acid using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC·HCl, 1.2 equivalents) and 1-hydroxybenzotriazole (HOBt, 1.2 equivalents) in DMF, providing entry to a chemical series in which the C-2 side chain stereochemistry and substitution pattern are systematically varied. The process underscores the dual reactivity of the bromoacetyl handle—first as a pronucleophile, then as an electrophilic displacement center—enabling the consolidation of multiple bond-forming events into a single synthetic sequence without intermediate chromatographic purification.

Solid-phase synthesis protocols employed in the preparation of encoded combinatorial libraries for high-throughput screening have adopted the bromoacetyl pyrrolidine as a diversity element anchored to Wang or 2-chlorotrityl chloride resin. Loading onto 2-chlorotrityl chloride resin (1.6 mmol/g substitution) proceeds via the free NH generated after Cbz removal. The benzyl carbamate protecting group is cleaved prior to loading using 33% hydrobromic acid in acetic acid at 0 °C for 1 hour, a method preferred over catalytic hydrogenation to avoid potential reduction of the bromoacetyl ketone to the alcohol. After liberation of the amine hydrobromide salt, neutralization with diisopropylethylamine (3.0 equivalents) in dichloromethane and immediate addition of the pre-swollen resin (1.0 g per 0.3 mmol of amine) in DMF ensures clean immobilization. The loading efficiency, determined by spectrophotometric measurement of the dibenzofulvene-piperidine adduct at 301 nm after Fmoc capping of unreacted sites, is typically 0.8 to 1.1 mmol/g.

With the pyrrolidine scaffold anchored through the ring nitrogen, the bromoacetyl group becomes a strategically positioned electrophile oriented away from the resin bead interior and fully accessible for sequential nucleophilic diversification. Library construction proceeds through a split-and-pool strategy: the first diversification employs a panel of 12 aliphatic and benzylic primary amines in N-methyl-2-pyrrolidone (NMP) at 60 °C, with each displacement reaction monitored by bromophenol blue color test on a small resin aliquot to confirm consumption of the alkyl bromide. After washing cycles (NMP, methanol, dichloromethane, each 3 × 2 minutes), the secondary amine is acylated with 8 distinct carboxylic acid building blocks using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU, 3.0 equivalents) and diisopropylethylamine (6.0 equivalents) in DMF for 2 hours at room temperature. Cleavage from the resin using 5% trifluoroacetic acid in dichloromethane (3 × 10 minutes) releases the final compounds into the filtrate; evaporation and preparative reversed-phase HPLC purification (C18, 30 × 150 mm, acetonitrile/water with 0.1% formic acid, gradient 10–90% over 20 minutes) yields individual library members in amounts of 5 to 25 mg with purity exceeding 95% by ELSD. The entire library—96 discrete compounds derived from a single starting building block—has been screened against a panel of kinase and GPCR targets in a 384-well format, with hit confirmation performed in dose-response (singlicate, 11-point serial dilution, starting concentration 10 μM) using homogeneous time-resolved fluorescence or luminescence-based assay technologies.

When the Pyrrolidine Scaffold Serves as a Chiral Auxiliary for Transient Oxazolidinone Formation

Synthetic sequences targeting neurokinin-1 (NK1) receptor antagonists incorporate the bromoacetyl pyrrolidine as a late-stage intermediate that simultaneously installs the necessary 3,4-trans-disubstituted pyrrolidine core and provides a functional handle for appending a heterocyclic head group. Acylative ring closure transforms the bromoacetyl moiety into an oxazole ring fused to the pyrrolidine at the C-3/C-4 positions without disturbing the benzyl carbamate protection at the ring nitrogen. Treatment of the bromoketone with ammonium acetate (5.0 equivalents) in acetic acid at 110 °C for 4 hours generates the oxazole via a condensation-dehydration pathway; the byproduct ammonium bromide precipitates from the cooled reaction mixture and is removed by filtration. The oxazole intermediate is then regioselectively halogenated at the 2-position using N-bromosuccinimide (1.0 equivalent) in DMF at 50 °C, providing the bromide necessary for a subsequent Suzuki-Miyaura cross-coupling with a functionalized phenylboronic acid.

Suzuki coupling is conducted under standard aqueous/organic biphasic conditions: tetrakis(triphenylphosphine)palladium(0) (3 mol%), the arylboronic acid (1.3 equivalents), and aqueous sodium carbonate (2 M, 3.0 equivalents) in toluene/ethanol (3:1 v/v) at reflux. The reaction proceeds cleanly; HPLC analysis after 2 hours indicates consumption of the oxazole bromide and formation of the coupled product. After Cbz hydrogenolysis, the free pyrrolidine nitrogen is attached via a methylene linker to a bis(trifluoromethyl)phenyl ring through reductive amination with the corresponding benzaldehyde and sodium triacetoxyborohydride in 1,2-dichloroethane. The final NK1 antagonist structure thus displays a 3-(oxazol-4-yl)-4-ethylpyrrolidine motif wherein the relative and absolute stereochemistry originate entirely from the bromoacetyl intermediate. In vitro binding affinity to the human NK1 receptor (membrane preparations from CHO cells stably expressing the human receptor, displacement of [¹²⁵I]Bolton-Hunter substance P, incubation 60 minutes at 25 °C) for compounds in this oxazole series is reported in the range of 0.3 to 1.1 nM, with pharmacokinetic profiling in beagle dogs (oral dose 1 mg/kg, cassette dosing format, n = 3) indicating oral bioavailability of 35–55% and a terminal elimination half-life of 4.5–7 hours. The synthetic strategy deliberately preserves the benzyl carbamate until the penultimate step, as the electron-withdrawing nature of the Cbz group suppresses racemization of the C-3 stereocenter during the high-temperature oxazole-forming condensation; removal of the protective group earlier in the sequence results in detectable epimerization of the C-3 position upon prolonged heating in acetic acid, as confirmed by chiral SFC analysis of the resulting diastereomeric mixture.

The structural features of the (3R,4S)-configured bromoacetyl pyrrolidine have been exploited in the design of covalent inhibitors targeting cysteine proteases where the bromoacetyl group serves as a warhead that irreversibly alkylates the active-site cysteine thiol. Docking simulations using cathepsin K crystal structures (PDB entry 1ATK, resolution 2.2 Å) position the pyrrolidine ring in the S2 pocket, with the C-4 ethyl substituent occupying a narrow hydrophobic groove that dictates strict enantiomeric specificity. The α-bromoketone is oriented toward Cys25 at a distance compatible with nucleophilic attack; irreversible inhibition proceeds via an S_N2 mechanism that expels bromide and forms a stable thioether linkage between the inhibitor and the enzyme. Kinetic analysis of enzyme inactivation follows a two-step model: an initial reversible binding event characterized by K_I, followed by covalent bond formation described by k_inact. For the benzylcarbamate-protected bromoketone, measured k_inact/K_I values are typically in the range of 4,000–12,000 M⁻¹s⁻¹ across different cysteine protease family members, conferring useful potency while maintaining a selectivity window over serine hydrolases that are not susceptible to alkylation by this chemotype.

Compound integrity verification prior to biochemical assays involves two orthogonal LC-MS methods: Method A employs an Acquity UPLC BEH C18 column (2.1 × 50 mm, 1.7 μm) with a 0.1% formic acid in water/acetonitrile gradient over 3 minutes; Method B uses a hydrophilic interaction chromatography (HILIC) column (BEH Amide, 2.1 × 100 mm, 1.7 μm) with an ammonium formate buffer/acetonitrile gradient over 5 minutes. A purity exceeding 95% area percent at 254 nm and correct mass confirmation (± 3 ppm mass accuracy) are required before the compound is released for assay. The reactivity of the bromoacetyl warhead necessitates the routine inclusion of a low-molecular-weight thiol quencher control—typically glutathione, 5 mM—in a parallel incubation to confirm that observed biochemical activity originates from specific active-site engagement rather than non-selective protein modification, a test specified in the assay validation protocol per institutional biochemical screening guidelines.